Genmab, the Denmark-based developer of antibody drugs, said today it has formed a second collaboration to use technology from Seattle Genetics (NASDAQ: [[ticker:SGEN]]) that’s designed to make antibodies more potent. Genmab will seek use the “empowered antibody” technology against a target known as CD74, which is found on various blood cancer and solid tumor cells. Seattle Genetics is getting an undisclosed upfront payment, and will have the right to co-develop and co-market the drug candidate after Genmab completes the first phase of clinical trials.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
